64 results about "Adenocarcinoma breast" patented technology

Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

The invention discloses an EGFR inhibitor. The EGFR inhibitor is of the structure shown in the formula (I) and is a compound including alpha, beta-unsaturated carboxylic acid amides. Meanwhile, the invention discloses a preparing method of the compound and the application of the compound serving as a protein tyrosine kinase inhibitor, especially the inhibiting function on T790M variant EGFR as the EGFR inhibitor, and the application on treating diseases such as the kidney cancer, the ling cancer, the prostate cancer, the pancreatic cancer the breast cancer and the spongiocytoma which are related to EGFR over expression. The structure is shown in the specification.

The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFP) and an inhibitor of programmed cell death protein 1 (PD-1) for treatingcancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer,kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and / or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.

The invention provides a novel substituted heteroaryl fused ring compound and a preparation method thereof, and the novel substituted heteroaryl fused ring compound can be used as a TRK inhibitor and has a wide and good application prospect in TRK kinase mediated diseases such as melanoma, lung cancer, head and neck cancer, pancreatic cancer, breast cancer, thyroid cancer and glioma.

An imaging, guidance, planning and treatment system integrated into a single unit or assembly of components, and a method for using same, that can be safely and effectively deployed to treat prostate cancer in all medical settings, including in a physician's office or in an outpatient setting. The system utilizes the novel process of Radio-Frequency Electrical Membrane Breakdown (“EMB” or “RFEMB”) to destroy the cellular membranes of unwanted or cancerous tissue without denaturing the intra-cellular contents of the cells comprising the tissue, thereby exposing tumor antigens and other intra-cellular components which can have an immunologic effect on local or distant cancerous tissue, with or without the addition of immunologic adjutant drugs. The system preferably comprises at least one EMB treatment probe 20, at least one trackable biopsy needle 200, at least one trackable anesthesia needle 300, and at least one controller unit for at least partially automating the treatment process.

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and / or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

The invention belongs to the field of medicinal chemistry, and particularly relates to phosphoglyceromutase 1. The invention provides an inhibitor of the phosphoglyceromutase 1; a specific structure is as shown in the formula I as shown in the description. The invention further provides a synthesis method of the structure as shown in the formula I as shown in the description and application in diseases related to cell apoptosis and tumors thereof; the diseases include various kinds of cancer of stomach cancer, liver cancer, myelomas, bladder cancer, prostatic cancer, breast cancer, rectal cancer, head and neck cancer, lung cancer, melanomas, ovarian cancer, cervical cancer, esophagus cancer and the like.

The present invention discloses a pyrido[2,3-d]pyrimidine compound represented by a general formula I or a pharmaceutically acceptable salt thereof. The general formula I is shown as the specification, wherein R1 is selected from one of an alkylamine group of C1-C6, an alicyclic amine group of C1-C6, a heterocyclic amine group of C1-C6, and an aromatic amine group of C6-C8, and X represents a hydrogen atom or a halogen atom. According to the invention, in-vitro cell activity tests prove that the compound provided by the invention has antitumor activity and can be used for preparing medicines for treating and / or preventing various cancers caused by BRaf kinase mutation, such as melanoma, thyroid cancer, breast cancer, liver cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, etc.

The invention disclosed herein is directed to compounds of Formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticδ leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (1a) or (1b), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPARα and PPARδ. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and / or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a herapeutically effective amount of a dual antagonist of PPARα and PPARδ.

The invention discloses a novel CDK4 / 6 inhibitor and a preparation method and application thereof.The novel CDK4 / 6 inhibitor is shown in the formula (I), has CDK4 / 6 inhibitory activity and has a treatment effect on CDK4 / 6 regulation related diseases including multiple myeloma, lung cancer, liver cancer, prostatic cancer, breast cancer and the like.

The invention discloses a polyether type compound and application of a chelation form thereof, a hydration form thereof or pharmaceutically acceptable salt thereof in preparation of medicines. The medicines are used for treating at least one of brain cancer, skin cancer, kidney cancer, bone cancer, sarcoma, prostate cancer, uterine cancer, melanotic carcinoma, colorectal cancer, lymph cancer, leukemia, pancreatic cancer, breast cancer, liver cancer, lung cancer, stomach cancer and ovarian cancer. The medicines have relatively good effect of preventing and treating tumors.

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and / or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

The invention discloses a selective inhibitor of a clinical mutant of EGFR protein tyrosine kinase, a diaromatic ring template compound containing thienopyrimidine having the structure shown in formulas (I and II) and a preparation method and application of the compound as the selective inhibitor of the clinical mutant of the EGFR protein tyrosine kinase. The selective inhibitor particularly has an inhibiting effect on an epidermal growth factor receptor EGFR of T790M mutation, and treats the diseases associated with the overexpression of the epidermal growth factor receptor EGFR such as the kidney cancer, the lung cancer, the prostate cancer, the pancreatic cancer, the breast cancer and glioma.

The invention relates to an application of a compound marsdenia tenacissima glycoside B which is extracted and separated from natural plant marsdenia tenacissima in the preparation of a drug for remedying tumour diseases including various malignant tumour diseases, such as ovary cancer, stomach cancer, liver cancer, leucocythemia, lung cancer, oral epidermoid carcinoma, rectal adenocarcinoma, breast cancer, malignant melanocarcinoma, colon adenocarcinoma, nasopharyngeal carcinoma, prostate cancer, etc. The invention also relates to a preparation technology of the marsdenia tenacissima glycoside B. After using water extraction and alcohol sedimentation, the invention uses an innovative chloroform extraction and aether sedimentation technology by chloroform extraction and also creatively adding aether, thereby reducing the content of impurity in extract obviously, and the marsdenia tenacissima glycoside B with high purity can be obtained just by silica gel column separation at a time. The method has high yield and simple operation, does not require a preparation type precision instrument of high performance liquid phase and other similar instruments and is closer to the requirement of the industrialized production.

The hedgehog (Hh) signaling pathway is a pathway which regulates patterning, growth and cell migration during embryonic development, but in adulthood is limited to tissue maintenance and repair. Mutational inactivation of the inhibitory pathway components leads to constitutive ligand-independent activation of the Hh signaling pathway, results in cancers such as basal cell carcinoma and medulloblastoma. Ligand-dependent activation of Hh signaling is involved in prostate cancer, pancreatic cancer, breast cancer and some blood cancers. Therefore, inhibition of the aberrant Hh signaling represents a promising approach toward novel anticancer therapy. The present invention provides novel molecules of formula I that inhibit hedgehog pathway signaling and provides therapeutic applications for the treatment of malignancies (basal cell carcinoma, medulloblastoma, glioblastoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, blood cancers, mesenchymal cancers, etc.), prevention of tumor regrowth, sensitization of radio-chemo therapies, and other diseases (inflammation, fibrosis and immune disorders) related to hedgehog signaling.

The invention relates to a sophoridine amine derivative, a preparation method thereof and an application, in particular to a compound as shown in a formula I, an optical isomer of the compound, a solvate of the compound or pharmaceutically acceptable salt of the compound. The compound is novel in structure and has excellent anti-tumor activity and good inhibitory activity for cancers such as liver cancer, lung adenocarcinoma, breast cancer, stomach cancer, colon cancer, cervical cancer, ovarian cancer, lymphoma, glioma, brain glioma and melanoma.

The invention discloses a heteroaryl compound and application thereof, and provides a heteroaryl compound as shown in a formula I, a tautomer, a stereoisomer or a pharmaceutically acceptable salt thereof. The compound has good tumor inhibition activity, especially on human chronic lymphocytic leukemia, lung adenocarcinoma, breast cancer, ovarian cancer, breast cancer or pancreatic cancer, and hasgood inhibitory activity on drug-resistant breast cancer, lung cancer, ovarian cancer or leukemia.

The invention disclosed herein is directed to compounds of Formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticδ leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (1a) or (1b), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a compound which is a dual antagonist of PPARα and PPARδ. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and / or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a therapeutically effective amount of a dual antagonist of PPARα and PPARδ.

The invention disclosed herein is directed to compounds of Formula Iand pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

The invention discloses a selective inhibitor of a clinical mutant of EGFR protein tyrosine kinase, the selective inhibitor is a triazine-containing double aromatic ring template compound and has a structure as shown in a formula (I), and the invention also discloses a preparation method of the compound and application of the compound as the selective inhibitor of the clinical mutant of the EGFR protein tyrosine kinase, in particular the inhibition effect on T790M variant epidermal growth factor receptor EGFR and the treatment of diseases such as renal cancer, lung cancer, prostate cancer, pancreatic cancer, breast cancer and glioblastoma related to overexpression of the epidermal growth factor receptor EGFR.

An N-(azaaryl) cyclic lactam-1-carboxamide derivative with a structure of formula (1) and its preparation method and application, the definition of each substituent is as described in the specification and claims. The compound can be widely used in the preparation of drugs for the treatment of cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, especially for the treatment of ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glial cell Drugs for tumors, multiple myeloma, metabolic diseases, neurodegenerative diseases, metastases from primary tumor sites, or bone metastatic cancers are expected to be developed into CSF1R inhibitor drugs.

The invention relates to an anti-tumour uracil compound and a lipid composition thereof. The invention provides a lipid composition comprising a compound shown in the formula (I), phospholipid, pegylated phospholipid, cholesterol and an excipient. The compound shown in the formula (I) is shown in the specification, wherein various substituent groups are shown in the specification. The invention also provides a method for preparing the lipid composition, a method for preparing the lipid composition from the compound shown in the formula (I) so as to improve the anti-tumour activity of an anti-tumour drug, and application of the lipid composition as an anti-tumour drug; for example, the lipid composition is used for colorectal cancer, prostate cancer, breast cancer, gastric cancer, ovarian cancer, chorionic epithelial cancer, malignant grape embryo, head and neck squamous cell carcinoma, skin cancer, liver cancer, bladder cancer, lung cancer, cervical cancer, liver cancer, biliary tract system tumour, pancreatic cancer and the like. The method and the lipid composition provided by the invention can effectively improve the anti-tumour activity of the drug; and the lipid composition prepared by the method provided by the invention shows excellent pharmaceutical properties.

Disclosed in the present invention is the use of a water soluble platinum complex in preparing drugs for the prevention and treatment of tumors, said platinum complex being shown as formula (I). Experiments have demonstrated that the present water soluble platinum complex alone or in combination with other chemotherapeutics is able to treat cancer in mammals, and in particular, humans, said cancers including lung cancer, colon cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoid cancer, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, gastric cancer, male genital cancer or bone cancer.

The invention discloses a furo pyrimidin di-aromatic nucleus derivative epidermal growth factor inhibitor, and a preparation method and applications thereof, and more specifically discloses a selective inhibitor of clinical mutants of EGFR protein tyrosine kinase. The selective inhibitor possesses structures represented by formula I and II, and is a di-aromatic nucleus template compound containingfuro pyrimidin. The invention also discloses a preparation method of the compound, applications of the compound as a selective inhibitor on clinical mutants of EGFR protein tyrosine kinase, and especially the inhibition effect of the compound on T790M mutation epidermal growth factor EGFR, and applications of the compound in treatment of diseases, such as kidney cancer, lung cancer, prostate cancer, pancreas cancer, breast cancer, and gliocytoma, related with epidermal growth factor EGFR excess expression.

The invention discloses a thiadiazole amide compound and application thereof, belonging to the field of medicines. The structural general formula of the compound is as shown in formula (I); the compound is a novel compound with androgen receptor antagonistic activity; and one of key targets is a binding pocket between dimer interfaces of an androgen receptor ligand binding domain, and the binding pocket can block androgen receptor dimerization so as to play a role in antagonizing an androgen receptor. The compound provided by the invention has relatively high activity of antagonizing androgen receptor transcription, shows relatively good biological activity at a molecular level, a cellular level and an animal level, and has relatively good safety. Therefore, the compound can be applied to preparation of drugs for treating androgen receptor abnormal expression tumors including but not limited to prostate cancer, metastatic prostate cancer, castration-resistant prostate cancer, breast cancer and ovarian cancer.

Disclosed are a composition and a perfume composition for inhibiting growth of breast cancer stem cells containing phenylacetaldehyde or a pharmaceutically acceptable salt thereof as an active (effective) ingredient, and a pharmaceutical composition, a food composition or the like for inhibiting metastasis of breast cancer, or treating or preventing breast cancer, including the composition. The phenylacetaldehyde inhibits growth of breast cancer cells and formation of breast cancer stem cells. In addition, the phenylacetaldehyde inhibits expression of self-renewal genes such as Nanog, Sox2, Oct4, and CD44 known to be specifically expressed in breast cancer stem cells, inhibits production of IL-6 known to be involved in formation of mammospheres of breast cancer stem cells, and inhibits STATS signaling pathways. Accordingly, the compound inhibits growth of breast cancer stem cells and is useful for the treatment of breast cancer.